Robert Chess - May 12, 2021 Form 4 Insider Report for NEKTAR THERAPEUTICS (NKTR)

Role
Director
Signature
Mark A. Wilson, Attorney-in-Fact
Stock symbol
NKTR
Transactions as of
May 12, 2021
Transactions value $
-$44,320
Form type
4
Date filed
5/14/2021, 06:05 PM
Next filing
Jun 25, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NKTR Common Stock Options Exercise $110K +8K +2.85% $13.80 289K May 12, 2021 Direct F1
transaction NKTR Common Stock Sale -$155K -8K -2.77% $19.34 281K May 12, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NKTR Stock Option Options Exercise $0 -8K -25% $0.00 24K May 12, 2021 Common Stock 8K $13.80 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 This transaction was executed in multiple trades at prices ranging from $19.16 to $19.56. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.